Organon is acquiring Dermavant, a company focused on dermatology, for up to $1.2 billion. Dermavant’s main asset is Vtama, a topical cream for plaque psoriasis that is also being reviewed for atopic dermatitis. Organon aims to expand the drug’s market and boost sales, although current projections have been lowered due to competition. Vtama’s mechanism of action could have applications in other skin disorders. Organon’s dermatology portfolio includes Diproson and Elocon. Roivant, Dermavant’s parent company, specializes in acquiring and developing drug assets. The deal with Organon includes upfront and milestone payments, royalties, and assumption of debt. Both companies see the acquisition as beneficial for expanding Vtama’s reach.
Source link
Organon Gets More Skin in the Game by Acquiring Roivant’s Dermatology Subsidiary
